Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/30/25 Summit Therapeutics (SMMT) Ivonescimab for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
5/30/25 Bristol (BMY) Opdivo for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
5/30/25 Pfizer (PFE) Braftovi for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
5/30/25 Novartis (NVS) Scemblix for Chronic Myelogenous Leukemia (CML) Subscribers Only Subscribers Only Subscribers Only
5/30/25 IN8Bio (INAB) INB-200 for Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/12/2025 Subscribers Only Subscribers Only Trial Data - Other
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update